RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.

XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.

Intellia reports better-than-expected fourth-quarter 2024 results. The company provides updates on its pipeline candidates.

BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.

DNLI reports a narrower-than-expected loss for the fourth quarter of 2024. Denali remains on track to submit a BLA for tividenofusp alfa for the...

Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.

CYTK reports a wider-than-expected Q4 loss as operating expenses increase. CYTK is gearing up to launch lead candidate aficamten upon a potential FDA...

SAM's fourth-quarter 2024 results reflect a wider-than-expected loss per share and a sales beat. Depletions remain flat year over year.

Ironwood reports weaker-than-expected results for the fourth quarter of 2024. The company maintains total revenue guidance for 2025.

IONS reports better-than-expected top and bottom-line numbers for the fourth quarter.